DFDA

Heparin/Lidocaine (intravesical)

Treatment for Interstitial Cystitis

Typical Dosage: Heparin 10,000-20,000 units + Lidocaine 1-2% 20mL intravesically

Effectiveness
62%
Safety Score
75%
Clinical Trials
8
Participants
1.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
Heparin 10,000-20,000 units + Lidocaine 1-2% 20mL intravesically
Time to Effect
Immediate (Lidocaine), 2-4 weeks (Heparin)
Treatment Duration
6-12 weeks induction, then maintenance
Evidence Quality
MODERATE
Confidence Score
68%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$500
Side Effect Mgmt:$50
Total Annual:$6,850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$13,700
Cost per Remission
$228,333.33
Heparin/Lidocaine (intravesical) Outcomes

for Interstitial Cystitis

Efficacy Outcomes
Overall Effectiveness
+62%
Response Rate
+50%
Remission Rate
+3%
Common Side Effects
Bladder discomfort
+30%
Urgency
+15%

Sources:

nih.gov
amegroups.org
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
4 active trials recruiting for Heparin/Lidocaine (intravesical) in Interstitial Cystitis

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

NCT05737121RECRUITINGPHASE2
View Study
120 participants
INTERVENTIONAL
Escondido, United States +13 more
Started: May 22, 2023

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)

NCT06394830RECRUITINGPHASE2
View Study
50 participants
INTERVENTIONAL
Tucson, United States +4 more
Started: Dec 13, 2024

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

NCT05658874ACTIVE NOT RECRUITINGPHASE3
View Study
26 participants
INTERVENTIONAL
Pittsburgh, United States
Started: Dec 1, 2022

Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

NCT02870738RECRUITINGPHASE2
View Study
128 participants
INTERVENTIONAL
Royal Oak, United States
Started: Apr 21, 2017
Completed Clinical Trials
2 completed trials for Heparin/Lidocaine (intravesical) in Interstitial Cystitis

Study of U101 for Bladder Pain and/or Urgency

NCT00256542COMPLETEDPHASE2
View Study
90 participants
INTERVENTIONAL
San Diego, United States +8 more
Started: Jan 1, 2006

Clinical Trial Comparing Two Bladder Instillations for IC/BPS

NCT03463915COMPLETEDPHASE3
View Study
90 participants
INTERVENTIONAL
Louisville, United States
Started: Jan 25, 2019